EGFR/DHFR-IN-2
EGFR/DHFR-IN-2 (9b) is a dual h-DHFR/EGFRTK inhibitor, with IC50 values of 0.192 μM and 0.109 μM for h-DHFR and EGFR, respectively. EGFR/DHFR-IN-2 (9b) halts the cell cycle at the G1/S phase and induces apoptosis. EGFR/DHFR-IN-2 (9b) is a potential inhibitor of CYP2C9 and CYP3A4. EGFR/DHFR-IN-2 (9b) can be used in the cancer research[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Cytochrome P450; Dihydrofolate reductase (DHFR) ; EGFR
Related Pathways
Apoptosis; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
CCOC(C1=CC=C(C=C1)N2C(N)=C(C3(C(C#N)=C2O)C(C4=CC=CC=C4C3=O)=O)C#N)=O
Molecular Formula
C24H16N4O5
Molecular Weight
440.41
References & Citations
[1]Ahmed Ragab, Discovery and optimization of 2-pyridones as dual h-DHFR/EGFRTK inhibitors with immunomodulatory potential; design, synthesis, anti-proliferative activity, and apoptosis inducer, et al. Eur J Med Chem. 2025 May 10:294:117751.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC942600-100 1x 100 µL
EGFRvIII (Epidermal Growth Factor Receptor, Variant III) (GFR/2600R), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details